Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

You might, but I don’t. I prefer R&D for more trials, studies, ANDAs and hopefully NDAs. Would be great to see ADT come to fruition too. Elite is annualizing close to $40M in annual rev. With additional CNS ANDA expansion + global opportunities, I don’t see why we can’t start pushing to annualize at $100M within a couple of years. That’s just on CNS side as Elite hasn’t yet pursued Concerta generic (Lannett has already) or Vyvanse (off patent June 2023). Those CNS opportunities by itself are big and Elite knows they have to diversify as well. Looking forward to seeing what gets filed late 2022/early 2023 as Elite starts diversifying.

If Elite survives a few years without being sold, I’d like to see a small, steady buyback and uplist to NASDAQ. I don’t think CEO is ready to sell quite yet. I think he wants to beef up Mikah with some valuable ANDAs so he can create a package deal. My two cents.